GoodRx Holdings (GDRX) Liabilities and Shareholders Equity (2019 - 2026)

GoodRx Holdings has disclosed Liabilities and Shareholders Equity across 8 years of filings, most recently posting $2.0 billion for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $2.0 billion, up 56.05% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.1 billion (up 10.08% YoY), and the FY2025 annual result was $1.4 billion, up 1.15% from the prior year.
• Liabilities and Shareholders Equity came in at $2.0 billion for Q1 2026 at GoodRx Holdings, up from $1.4 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $2.0 billion in Q1 2026 to a low of $1.3 billion in Q1 2025.
• The 5-year median for Liabilities and Shareholders Equity is $1.5 billion (2022), against an average of $1.5 billion.
• Across the five-year window, Liabilities and Shareholders Equity fell 20.68% in 2024 and soared 56.05% in 2026, its largest moves.
• GoodRx Holdings' Liabilities and Shareholders Equity stood at $1.6 billion in 2022, then retreated by 0.99% to $1.6 billion in 2023, then retreated by 12.63% to $1.4 billion in 2024, then rose by 1.15% to $1.4 billion in 2025, then surged by 43.96% to $2.0 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $2.0 billion (Q1 2026), $1.4 billion (Q4 2025), and $1.3 billion (Q3 2025), per Business Quant data.